Bing

SEARCH HISTORY

Johnson & Johnson’s third-quarter earnings rose 59% on higher pharmaceutical sales despite a stronger U.S. dollar and new competition that held back its Olysio hepatitis C drug. J&J, which makes a range of health-care products including prescription ...
Wall Street Journal · ByTess Stynes · 10/15/2014
Johnson & Johnson (JNJ) is a publicly traded company. It has been listed on New York Stock Exchange since 1944. Its common stock is part of the Dow Jones Industrial Average. The company is one of the Fortune 500 companies. Johnson & Johnson’s …
Market Realist · 3/12/2015
[In that spirit, Zach Scheidt presents ... like Johnson & Johnson (JNJ), Coca-Cola (KO) and Wal-Mart (WMT). The last few years have featured a “reach for yield” as these conservative investors have moved money into the stock market to try to get ...
The Daily Reckoning · 2/18/2015
More from Bing News
The deal -- the latest example of a big drugmaker swooping on a biotech firm to refill its medicine pipeline -- confounds expectations that Pharmacyclics would sell out to Johnson & Johnson (JNJ.N). AbbVie will pay $261.25 per share in cash and stock ...
Reuters · BySupriya Kurane · 3/5/2015
If you look at Medivation's stock chart, however ... PREVAIL was also a huge success and is one reason why Xtandi is displacing Johnson & Johnson's (JNJ) competitive drug Zytiga in the pre-chemo setting. In the PREVAIL trial, the median patient was ...
Minyanville · 2/4/2015
Of course, there are always disappointments from quarter to quarter. Johnson & Johnson (NYSE/JNJ) didn’t have a particularly great quarter recently. And neither did 3M Company (NYSE/MMM). But while international businesses are feeling the effects of a ...
Smallcap Network · 4/27/2015
Value investing involves selecting companies whose stock prices seem to be lower than expected ... General Electric (GE), 2.45%; and Johnson & Johnson (JNJ), 2.36%. This fund provides a simple way to include a value-oriented strategy in your portfolio ...
Townhall Finance · 4/4/2015
In connection with Pulmatrix's entry into the merger agreement, certain existing institutional investors in Pulmatrix entered into stock purchase agreements with ... which was acquired by Johnson & Johnson (JNJ); and Cubist Pharmaceuticals, which was ...
News-Medical · 3/16/2015
Healthcare giant Johnson & Johnson said ... price range was $86.09 to $109.49. The stock price rise over the year and the results announced Tuesday probably will help Gorsky's personal finances. According to the JNJ proxy statement filed with the ...
Philadelphia Daily News · 1/20/2015
Isis Pharmaceuticals Inc. said Monday it had inked a licensing agreement to develop drugs to treat autoimmune disorders of the gastrointestinal tract -- a collaboration with Johnson & Johnson Inc. (JNJ)'s Janssen ... shares of stock and an upfront license ...
The Deal Pipeline · 1/6/2015